← All trials
NCT05310734
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 4, 2022
- Primary completion
- Aug 31, 2022
- Completion date
- Feb 28, 2023
- First posted
- Apr 5, 2022
- Last posted
- Apr 5, 2022
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cipher Pharmaceuticals Inc.Lead sponsor
- ParaProLead sponsor
- Concentrics ResearchCollaborator
- Concentrics ResearchOverall official - principal investigator
- Concentrics ResearchStudy chair
- IQVIACollaborator
- Medpace, Inc.Collaborator
- ParaProStudy director
- Concentrics ResearchOfficial
- ParaProOfficial
- Cipher Pharmaceuticals Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.